Xytis is a mid-stage, privately-held, venture capital-funded biotechnology company, based in Irvine, California.

Xytis aims to discover and develop a balanced portfolio of unique in-licensed clinical-stage compounds and internally-discovered novel IND-candidates for the treatment of central nervous system (CNS) disorders.

The company’s strategy is to bring novel chemical entities for validated  targets from discovery to phase III.

Mission and Vision 

The Mission of Xytis is to make a significant contribution to patients suffering from CNS disorders for which there are unmet medical needs.

The Vision of Xytis is to be a leading international CNS drug discovery and development company. Xytis intends to create novel clinically meaningful medicines for CNS indications in order to the improve quality of life of patients, create commercial value for the company's shareholders and employees, and build a high performance organization fostering team spirit, personal growth and professional integrity.